Hjem › Kronisk lymfatisk leukemi › Tennessee › Nashville
Kliniske studier for Kronisk lymfatisk leukemi i Nashville, TN
13 studier for Kronisk lymfatisk leukemi søker deltakere på steder i og rundt Nashville (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RekruttererFase 3
- Tennessee Oncology, Nashville
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RekruttererFase 3
- Tennessee Oncology, Pllc Nashville, Nashville
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RekruttererFase 3
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RekruttererFase 2
- SCRI Oncology Partners, Nashville
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
RekruttererFase 3
- SCRI Oncology Partners, Nashville
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
RekruttererFase 1/2
- SCRI Oncology Partners, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RekruttererFase 3
- Sarah Cannon Research Institute SCRI, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- TriStar BMT, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- Tennessee Oncology, Nashville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekruttererFase 4
- Tennessee Oncology, Nashville
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekruttererFase 4
- Tennessee Oncology, Nashville
HPC Offered for PRESERVE Expansion
RekruttererObservasjonsstudie
- Tristar Centennial Medical Center, Nashville
Kronisk lymfatisk leukemi-studier i andre byer
- Boston, MA31 studier
- Columbus, OH28 studier
- Durham, NC27 studier
- Washington, DC22 studier
- Seattle, WA20 studier
- Rochester, MN18 studier
- New York City, NY18 studier
- Houston, TX17 studier
- Baldwin Park, CA16 studier
- Milwaukee, WI15 studier
- Chicago, IL14 studier
- Cincinnati, OH14 studier
Andre studier i Nashville
- Ikke-småcellet lungekreft97 studier
- Brystkreft81 studier
- Metastatisk kreft70 studier
- Kolorektal kreft69 studier
- Kreft (alle typer)65 studier
- Eggstokkreft49 studier
- Prostatakreft43 studier
- Lungekreft40 studier
- Plateepitelcancer i hode og hals39 studier
- Pankreaskreft39 studier
- Endometriekreft38 studier
- Melanom33 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.